港股異動丨東陽光藥今年以來累跌約35% 今年一季度業績差強人意
格隆匯4月29日丨東陽光藥(1558.HK)跌逾4%,連續4個交易日下跌,今年以來股價累計跌幅約35%,在今年醫藥股普漲的大環境下顯得黯然失色,總市值128.4億港元。東陽光藥公佈,截至2020年3月31日止第一季度,實現營業收入20.11億元,同比增長5.57%;歸屬於公司權益持有人的溢利及全面收益總額(不考慮可轉換債券影響)3.20億元,同比增長11.60%;歸屬於公司權益持有人的溢利及全面收益總額(考慮可轉換債券影響)7.81億元,同比增長0.68%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.